Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655

Clinical Trial Grant

Duke Scholars

Principal Investigator Thomas Eldridge Stinchcombe Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Nuvalent, Inc.

Start Date

March 17, 2023

End Date

October 31, 2027

Administered By

Duke Cancer Institute

Awarded By

Nuvalent, Inc.

Start Date

March 17, 2023

End Date

October 31, 2027